EHA 2020 | Edition virtuelle

Communication orales LYSA	ASCO 2020
C Herbaux	Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA Abstract
S Le Gouill	Ibrutinib, Venetoclax plus Obinutuzumab in newly diagnosed Mantle Cell Lymphoma Patients Abstract

Communication orales LYSA

ASCO 2020

C Herbaux

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA

Abstract

S Le Gouill

Ibrutinib, Venetoclax plus Obinutuzumab in newly diagnosed Mantle Cell Lymphoma Patients

Abstract